Table 2.
Demographics and baseline characteristics – (Safety population).
| Parameter | Phase 2 |
Phase 3 |
||
|---|---|---|---|---|
| SII-NVX-CoV2373 (N = 150) | Placebo (N = 50) | SII-NVX-CoV2373 (N = 1046) | NVX-CoV2373 (N = 350) | |
| Age (Years), Mean (SD) | 33.4 (9.47) | 34.5 (9.08) | 34.8 (10.80) | 33.4 (10.18) |
| Sex, n (%) | ||||
| Male | 111 (74.0) | 32 (64.0) | 602 (57.6) | 209 (59.7) |
| Female | 39 (26.0) | 18 (36.0) | 444 (42.4) | 141 (40.3) |
| Baseline SARS-CoV-2 serology and/or RT-PCR results, n (%)a | ||||
| Positive | 22 (14.7) | 6 (12.0) | 335 (32.0) | 118 (33.7) |
| Negative | 128 (85.3) | 44 (88.0) | 709 (67.8) | 231 (66.0) |
| Co-morbidities, n (%) | 20 (13.3) | 5 (10.0) | 134 (12.8) | 38 (10.9) |
a
Results missing in 2 and 1 participants in the two groups in Phase 3 study, respectively.